Pharmas Say FTC Pushing Subpoena Limits In AndroGel Row
The Federal Trade Commission can't justify its call for nationwide subpoena power in the agency's suit alleging the makers of testosterone drug AndroGel cut deals with generic companies to delay competition,...To view the full article, register now.
Already a subscriber? Click here to view full article